Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Non-Current Assets (2017 - 2021)

Cogent Biosciences has reported Non-Current Assets over the past 5 years, most recently at $7.9 million for Q3 2021.

  • Quarterly results put Non-Current Assets at $7.9 million for Q3 2021, up 22.11% from a year ago — trailing twelve months through Sep 2021 was $26.6 million (down 11.79% YoY), and the annual figure for FY2020 was $6.0 million, down 32.02%.
  • Non-Current Assets for Q3 2021 was $7.9 million at Cogent Biosciences, up from $7.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for COGT hit a ceiling of $11.4 million in Q1 2019 and a floor of $4.9 million in Q4 2018.
  • Median Non-Current Assets over the past 5 years was $7.1 million (2020), compared with a mean of $7.5 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 90.84% in 2019 and later plummeted 34.85% in 2020.
  • Cogent Biosciences' Non-Current Assets stood at $6.7 million in 2017, then dropped by 26.89% to $4.9 million in 2018, then skyrocketed by 79.33% to $8.8 million in 2019, then crashed by 32.02% to $6.0 million in 2020, then skyrocketed by 31.26% to $7.9 million in 2021.
  • The last three reported values for Non-Current Assets were $7.9 million (Q3 2021), $7.2 million (Q2 2021), and $5.5 million (Q1 2021) per Business Quant data.